GlassScriptPhysician profile
Sonal Parikh
NPI 1144607136
$2,874.83
in general payments reported to CMS, 2019-2025
22 companies · $902 in 2025
The $902 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.33 · 2020: $43.54 · 2021: $263 · 2022: $532 · 2023: $387 · 2024: $650 · 2025: $902.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,939.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,938.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $677.43 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Incyte Corporation | $339.55 | 2022-2025 | Opzelura |
| Abbvie INC. | $315.51 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $246.16 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $237.94 | 2021-2025 | Dupixent |
| Galderma Laboratories, L.P. | $187.01 | 2021-2025 | Aklief, Oracea, Twyneo |
| Sun Pharmaceutical Industries INC. | $149.15 | 2021-2024 | Ilumya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.97 | 2024-2025 | Spevigo |
| Allergan, INC. | $97.33 | 2019 | |
| Genzyme Corporation | $96.43 | 2025 | |
| Ucb, INC. | $84.51 | 2021-2025 | Bimzelx |
| Pfizer INC. | $53.09 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $49.91 | 2024-2025 | Zoryve |
| Lilly USA, LLC | $48.59 | 2025 | Ebglyss, Taltz |
| Amgen INC. | $36.65 | 2024 | Otezla |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $22.16 | 2021 | |
| Almirall LLC | $21.10 | 2025 | Seysara |
| Leo Pharma INC. | $19.92 | 2025 | Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $19.49 | 2024 | Sotyktu |
| Botanix Sb INC | $17.83 | 2025 | Sofdra |
| Convatec INC. | $17.82 | 2024 | |
| Organogenesis INC. | $16.28 | 2025 | Affinity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonal Parikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.